Market Exclusive

United Therapeutics Corporation (NASDAQ:UTHR) Files An 8-K Other Events

United Therapeutics Corporation (NASDAQ:UTHR) Files An 8-K Other Events
Item 8.01. Other Events.

On April8, 2019, United Therapeutics Corporation issued a press release announcing that its BEAT study of esuberaprost did not meet its primary endpoint. A copy of the press release is attached hereto as Exhibit99.1 and incorporated herein by reference.

Item 9.01. Exhibits

(d) Exhibits

ExhibitNo.

DescriptionofExhibit

99.1

Press Release dated April8, 2019

UNITED THERAPEUTICS Corp Exhibit
EX-99.1 2 a19-7981_1ex99d1.htm EX-99.1 Exhibit 99.1   Contact: James Edgemond Phone: (301) 608-9292 E-mail: jedgemond@unither.com   UNITED THERAPEUTICS ANNOUNCES BEAT STUDY OF ESUBERAPROST DOES NOT MEET PRIMARY ENDPOINT   Silver Spring,…
To view the full exhibit click here

About United Therapeutics Corporation (NASDAQ:UTHR)

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb). Its Prostacyclin Analogues lead product is Remodulin (treprostinil) Injection. It also includes Tyvaso (treprostinil) Inhalation Solution and Orenitram (treprostinil) Extended-Release Tablets. Its subsidiary is developing another oral prostacyclin analogue for the treatment of pulmonary arterial hypertension (PAH) called esuberaprost. Its PDE-5 inhibitor is Adcirca (tadalafil) tablets are indicated for the treatment of PAH. Its Unituxin (dinutuximab) Injection in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2 and 13-cis-retinoic acid is indicated for the treatment of pediatric patients with neuroblastoma.

Exit mobile version